Catcher Technology (2474) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
31 Mar, 2026Executive summary
Revenue in 2Q25 rose 16.9% quarter-over-quarter and 8.8% year-over-year to NT$5.084bn, driven by inventory buildup due to US tariff concerns and medtech contributions.
Net profit after tax (NPAT) was -NT$1.03bn, a sharp decline from NT$2.92bn in 1Q25 and NT$3.44bn in 2Q24, mainly due to significant FX losses and lower gross margin.
Basic EPS dropped to -NT$1.60 in 2Q25 from NT$4.46 in 1Q25 and NT$5.05 in 2Q24.
1H25 NPAT was NT$1.887bn, down 76% y-o-y; basic EPS was NT$2.91 (vs. NT$11.77 in 1H24).
Financial highlights
2Q25 EBITDA was NT$1.27bn, up 1.6% q-o-q but down 11% y-o-y.
2Q25 gross margin was 30.5% (down from 35.0% in 1Q25 and 34.0% in 2Q24).
Operating profit for 2Q25 was NT$905mn, down 5% y-o-y.
Non-operating losses in 2Q25 totaled NT$1.675bn, mainly due to NT$3.448bn in FX losses.
Cash and cash equivalents at June 30, 2025 were NT$22.4bn, down from NT$28.4bn in 2Q24 and NT$50.4bn at year-end 2024.
Outlook and guidance
Ongoing diversification into medtech, semiconductor, and aerospace sectors, with significant investments planned over the next 5-10 years.
Overseas expansion includes new facilities in Thailand and Vietnam, with mass production in Thailand expected in 2026-2027.
Strategic focus on R&D, product certifications, and M&A to drive long-term growth.
Management continues to monitor economic conditions and aims for stable dividend growth and sustainable operations.
Latest events from Catcher Technology
- H1 2024 net profit rose 49% despite a 20% revenue drop, supported by FX gains and strong liquidity.2474
Q2 202431 Mar 2026 - Net profit jumped 44% to NT$13.20bn on stable revenue, margin gains, and high dividends.2474
Q4 202431 Mar 2026 - Q3 2024 revenue and margins rose, but net profit and cash fell amid FX losses and capital returns.2474
Q3 202431 Mar 2026 - Gross margin reached 35% as revenue grew 18.9% year-over-year, but net profit fell sharply.2474
Q1 202531 Mar 2026 - 3Q25 net profit more than doubled year-over-year despite a 5% revenue decline.2474
Q3 202531 Mar 2026 - 4Q25 revenue fell, but gross margin rose; 2025 profit and EPS dropped despite medtech growth.2474
Q4 202531 Mar 2026